Inscobee Inc. 的 Form 4/A 修正申報
修正Apimeds Pharmaceuticals US, Inc.（APUS），2025/6/11 申報
- 申報編號
- 0001474506-25-000109
- 申報時間
- 2025/6/11 16:36 ET
- 交易日
- 2025/5/12
- 申報延遲
- 30 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2025/5/14
這份申報列了 2 筆非衍生性交易、2 筆衍生性交易。沿用原件裡沒有重述的 3 筆交易。公開市場買進合計 $200.0 萬。交易後 30 天申報。
這份修正申報重述了 0001474506-25-000089（2025/5/14 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Inscobee Inc.CIK 0002057997 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/5/12 | Common Stock, par value $0.01 per share | C轉換取得 | +71,090 | $2.60 | +$184,834 | 2,055,706 | 直接 | |
| 2025/5/12 | Common Stock, par value $0.01 per share | C轉換取得 | +44,041 | $2.60 | +$114,506.6 | 2,099,747 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/5/12 | Common Stock, par value $0.01 per share | C轉換取得 | +71,090 | $0.00 | – | 0 | 直接 | |
| 2025/5/12 | Common Stock, par value $0.01 per share | C轉換取得 | +44,041 | $0.00 | – | 0 | 直接 |
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0001474506-25-000089（2025/5/14 申報）。
非衍生性證券（表 I）
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/5/12 | Common Stock, par value $0.01 per share | P買進取得 | +500,000 | $4.00 | +$2,000,000 | 1,984,616 | 直接 | |
| 2025/5/12 | Common Stock, par value $0.01 per share | C轉換取得 | +182,002 | $2.60 | +$473,205.2 | 4,316,618 | 間接 |
衍生性證券（表 II）
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/5/12 | Common Stock, par value $0.01 per share | C轉換處分 | −182,022 | $0.00 | – | 0 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
On March 21, 2022, Apimeds Pharmaceuticals US, Inc. (the "Issuer") issued to Inscobee Inc. ("Inscobee") a convertible promissory note in the principal amount of $160,000 (as amended, the "March 2022 Note"). All outstanding principal and accrued and unpaid interest owed under the March 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of an offering of the Issuer's common stock resulting in the listing of the Issuer's common stock on the NYSE American, or other national securities exchange (a "Qualified Offering"). The March 2022 Note bears interest at an annual rate of 5%. The March 2022 Note is convertible into shares of common stock at a conversion price of $2.60 per share (the "Conversion Price"). The amount reported in Column 3 of Table II represents the original principal amount of $160,000, plus $24,833 of accrued and unpaid interest.
- F2
On May 12, 2025, the Issuer completed a Qualified Financing and all outstanding principal and accrued and unpaid interest owed under the note converted into common stock at the Conversion Price.
- F3
On June 3, 2022, the Issuer issued to Inscobee a convertible promissory note in the principal amount of $100,000 (as amended, the "June 2022 Note"). All outstanding principal and accrued and unpaid interest owed under the June 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of a Qualified Offering. The June 2022 Note bears interest at an annual rate of 5%. The June 2022 Note is convertible into shares of common stock at the Conversion Price. The amount reported in Column 3 of Table II represents the original principal amount of $100,000, plus $14,507 of accrued and unpaid interest.
備註
On May 14, 2025, the reporting person filed a Form 4, which incorrectly reported that the reporting person had indirect beneficial ownership of the Convertible Promissory Note in the amount of $184,833 (the "Note") and the shares of common stock underlying such Note (the "Shares"), through Apimeds Korea. In fact, as reported in this amendment, the reporting person directly owned the Note and the Shares.